XORTX Therapeutics Inc ( (TSE:XRTX) ) has released a notification of late filing.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
XORTX Therapeutics Inc. has announced a delay in filing its Form 20-F (Yearly Report) for the financial period ending December 31, 2024. The primary reason for this delay is the additional time required to complete financial reporting, closing procedures, and other disclosure items. The company has communicated that it expects to file the report on or before the fifteenth calendar day following the prescribed due date. Importantly, XORTX does not anticipate any significant changes in its financial results compared to the previous fiscal year. The company is actively working to ensure compliance, and the notification was signed by Michael Bumby, the Chief Financial Officer.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.
The overall stock score for XORTX Therapeutics Inc is low, driven primarily by its poor financial performance with no revenue and consistent losses. The technical analysis indicates bearish market conditions, further weighing down the score. Valuation metrics also reflect a negative assessment as the P/E ratio is negative, with no dividends to offset the lack of earnings. The combination of these factors suggests significant challenges ahead for the company.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
YTD Price Performance: -15.06%
Average Trading Volume: 7,218
Technical Sentiment Signal: Buy
Current Market Cap: C$5.34M
Learn more about XRTX stock on TipRanks’ Stock Analysis page.